Suppr超能文献

阿尔茨海默病中突触密度与“A/T/N”生物标志物的相关性:一项 F-SynVesT-1 PET/MR 研究。

The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An F-SynVesT-1 PET/MR study.

机构信息

Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.

Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

J Cereb Blood Flow Metab. 2024 Jul;44(7):1199-1207. doi: 10.1177/0271678X241230733. Epub 2024 Jan 31.

Abstract

A newly developed SV2A radiotracer, F-SynVesT-1, was used in this study to investigate synaptic density and its association with Alzheimer's disease (AD) "A/T/N" biomarkers. The study included a cohort of 97 subjects, consisting of 64 patients with cognitive impairment (CI) and 33 individuals with normal cognition (CU). All subjects underwent F-SynVesT-1 PET/MR and F-florbetapir PET/CT scans. Additionally, a subgroup of individuals also underwent F-MK-6240, F-FDG PET/CT, plasma Aβ42/Aβ40 and p-tau181 tests. The differences in synaptic density between the groups and the correlations between synaptic density and AD "A/T/N" biomarkers were analyzed. The results showed that compared to the CU group, the CI with Aβ+ (CI+) group exhibited the most pronounced synapse loss in the hippocampus, with some loss also observed in the neocortex. Furthermore, synaptic density in the hippocampus and parahippocampal gyrus showed associations with AD biomarkers detected by both imaging and plasma tests in the CI group. The associations between synaptic density and FDG uptake and hippocampal volume were also observed in the CI+ group. In conclusion, the study demonstrated significant synaptic density loss, as measured by the promising tracer F-SynVesT-1, and its close correlation with "A/T/N" biomarkers in patients with both Alzheimer's clinical syndrome and pathological changes.

摘要

本研究采用一种新开发的 SV2A 放射性示踪剂 F-SynVesT-1,旨在研究突触密度及其与阿尔茨海默病(AD)“A/T/N”生物标志物的关联。该研究纳入了 97 名受试者,包括 64 名认知障碍(CI)患者和 33 名认知正常(CU)个体。所有受试者均接受了 F-SynVesT-1 PET/MR 和 F-florbetapir PET/CT 扫描。此外,一部分个体还接受了 F-MK-6240、F-FDG PET/CT、血浆 Aβ42/Aβ40 和 p-tau181 检测。分析了组间突触密度的差异以及突触密度与 AD“A/T/N”生物标志物之间的相关性。结果表明,与 CU 组相比,Aβ+(CI+)组的 CI 患者表现出最明显的海马突触丢失,而新皮质也有一定程度的丢失。此外,CI 组中,海马和海马旁回的突触密度与通过成像和血浆检测到的 AD 生物标志物相关。在 CI+ 组中,还观察到突触密度与 FDG 摄取和海马体积之间的相关性。总之,本研究表明,在具有阿尔茨海默病临床综合征和病理改变的患者中,新的 SV2A 放射性示踪剂 F-SynVesT-1 测量的突触密度显著降低,且与“A/T/N”生物标志物密切相关。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验